Tag: Treatment

 

Indigenous mobile health unit combines traditional and modern medicine for treatment

TORONTO —
A mobile health unit in Toronto is combining traditional Indigenous treatments and modern medicine to help care for the city’s homeless and most vulnerable people.

Anishnawbe Health Toronto developed its mobile health unit after witnessing a rise in homelessness and overdoses brought on by the COVID-19 pandemic. The nurses, doctors and social workers tour the city’s homeless encampments and other areas to test and treat people in need of medical attention.

“We are providing COVID testing and for people that are homeless, transient and living rough, and also primary health care,” Jane Harrison with the Anishnawbe Health Toronto Mobile Unit told CTV News.

The system allows the health unit to track and care for the people who are experiencing homelessness and may have contracted COVID-19, while also affording them the ability to travel to where they’re needed most.

Now, the mobile health unit typically sees about 100 people per day.

“You can find 50 (to) 60 tents in some of these parks,” said Harvey Manning, director of Programs and Services at Anishnawbe Health Toronto. “What has happened is a lot of drop-in’s have closed. There’s fewer places for people to eat.”

Anishnawbe Health Toronto began in 1984 after its founder, Joe Sylvester, realized a “more comprehensive approach to health care” was needed among the Indigenous community in Toronto.

The health unit promotes traditional forms of Indigenous medicine and practices and offers its patients access to traditional healers, elders and medicine people, along with dentists, chiropractors and massage therapists. The health unit also helps people looking to “escape homelessness.”

“Anishnawbe Health has saved my life,” said Bonnie Gegwetch, a client of the organization.

For Gegwetch, having access to Anishnawbe Health Toronto has helped her to connect with her roots.

“I’m part of the 60s scoop,” she said. “This is my culture, this is where I found it.”

“Anishnawbe health has done an awesome job.”

The health unit is currently fundraising to put all of its services in one new building in downtown Toronto. Construction on the new facility is set to begin later this year.

Wiith files from CTV National News and Indigenous Circle reporter Donna Sound

Source Article

Remdesivir, first COVID-19 drug treatment, gets FDA approval

U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an IV.

The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

It had been authorized for use on an emergency basis since spring, and now becomes the first drug to win full Food and Drug Administration approval for treating COVID-19. President Donald Trump received it when he was sickened earlier this month.

Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who are hospitalized for a coronavirus infection. For patients younger than 12, the FDA will still allow the drug’s use in certain cases under its previous emergency authorization.

The drug works by inhibiting a substance the virus uses to make copies of itself. Certain kidney and liver tests are required before starting patients on it to ensure it’s safe for them and to monitor for any possible side effects. And the label warns against using it with the malaria drug hydroxychloroquine, because that can curb its effectiveness.

“We now have enough knowledge and a growing set of tools to help fight COVID-19,” Gilead’s chief medical officer, Dr. Merdad Parsey, said in a statement.

The drug is either approved or has temporary authorization in about 50 countries, he noted.

Its price has been controversial, given that no studies have found it improves survival. Last week, a large study led by the World Health Organization found the drug did not help hospitalized COVID-19 patients, but that study did not include a placebo group and was less rigorous than previous ones that found a benefit. The FDA’s approval statement noted that, besides the NIH-led one, two other studies found the drug beneficial.

Gilead charges $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

So far, only steroids such as dexamethasone have been shown to cut the risk of dying of COVID-19. The FDA also has given emergency authorization to using the blood of survivors, and two companies are currently seeking similar authorization for experimental antibody drugs.

Source Article

Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), by Disease Type (Atypical Absence Seizures and Typical Absence Seizures) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p05913817/?utm_source=GNW

The Global Childhood Absence Epilepsy Treatment Market is expected to grow from USD 181.92 Million in 2019 to USD 263.89 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.39%.

Market Segmentation & Coverage:
This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Childhood Absence Epilepsy Treatment Market studied across Lamotrigine, Phase 2 Drugs, and Valproate.

Based on Disease Type, the Childhood Absence Epilepsy Treatment Market studied across Atypical Absence Seizures and Typical Absence Seizures.

Based on Geography, the Childhood Absence Epilepsy Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Childhood Absence Epilepsy Treatment Market including AbbVie, Cavion, Inc., GlaxoSmithKline plc, Insys Therapeutics, Pfizer Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain,

Blood test may identify pancreatic cancers that will respond to treatment, researchers say

Oct. 22 (UPI) — Researchers have developed a simple blood test to identify pancreatic cancers that are more likely to respond to treatment than others, according to a paper published Thursday by Clinical Cancer Research.

The test detects and measures the levels of a sugar called sTRA, which is produced by some types of pancreatic cancer and escapes into the bloodstream. Pancreatic cancers that produce sTRA often do not respond to chemotherapy, the researchers said.

Testing prostate cancer patients for sTRA one day could guide treatment decisions, sparing patients with untreatable cancers from undergoing unnecessary therapies and experiencing potential side effects.

“Knowing which type of pancreatic cancer a person has is critical to implementing the right treatment strategy for each patient,” one of the researchers, Brian Haab, said in a statement.

“We hope that our new test, which detects a marker produced by cancer cells of one subtype and not the other, will one day soon be a powerful tool to help physicians and patients make the best decisions possible,” said Haab, a professor at the Van Andel Institute in Michigan.

About 60,000 people in the United States are diagnosed with pancreatic cancer annually and nearly 50,000 people die from it each year, according to the National Cancer Institute.

Pancreatic cancers are among the most challenging malignancies to treat, due in part to their ability to evade detection until they have advanced and spread.

No reliable way exists to determine whether a patient has a type of pancreatic cancer that will respond to existing chemotherapies, and the result often is a blanket treatment approach that works in some patients but can leave all with troubling side effects.

The new sTRA test evolved from an earlier test that combined an existing diagnostic approach designed to detect a sugar called CA19-9 with a new one that detected sTRA.

The combination approach detected nearly 70% of pancreatic cancers with a less than 5% false-positive rate — roughly 30% more than the CA19-9 alone, the researchers said.

Both the combination test and the new sTRA test still need to undergo further clinical studies to confirm their accuracy, they said.

“The … combination test tells us whether there is cancer, and the new sTRA test helps us determine what kind of pancreatic cancer, which then could allow physicians to better narrow down the appropriate treatment plan,” Haab said.

“When used in sequence, we believe the combination test and the new sTRA test could help catch and identify pancreatic cancer more quickly and definitively,” he said.

Source Article

Mom-Of-Four Dies At 31 After Cancer Treatment Canceled During Coronavirus Lockdown

Coronavirus pandemic has resulted in diagnoses and treatments being put on hold or delayed, resulting in the deterioration or even death of several patients. One such patient was a woman battling brain cancer who died after her chemotherapy was paused during the coronavirus lockdown in the United Kingdom.

The woman, identified as 31-year-old Emma Jenkinson, was suffering from grade 4 brain cancer, a condition she had previously beaten in her early 20s.

Her treatment was put on hold after the pandemic hit the country in March this year. Her condition deteriorated and she died earlier this month, leaving her four children and husband behind.

“She has grade four brain cancer and unfortunately her chemotherapy was paused in March due to covid19, before this, the cancer was reacting well to treatment,” her husband Andrew wrote on a GoFundMe page set up to raise funds for the woman’s family.

“At the beginning of May, Emma started feeling really unwell. She started losing her balance, falling over. At its worst she was falling 15-20 times a day. She actually fell over in the garden quite heavily and banged her head on a post so I had to rush her to A&E. It was later in the month she had a scan and found that the cancer had increased and was placed on chemotherapy straight away,” he added.

Her condition deteriorated in September.

“Unfortunately in September she started getting pressure in her head and feeling unwell again and after another scan she was told that the chemotherapy has stopped working,” he wrote.

They were then informed by the doctor that her surgery cannot be conducted as it will cause lot damage and affect her quality of life.

She died the following month. 

Calling her a “fantastic mother,” Andrew wrote, “All Emma wants like any mother is for her children to be healthy & happy in the future. All she wants is for the children to have happy memories of her and us all together.”

cancer chemo In this photo, patient receives chemotherapy treatment for breast cancer at the Antoine-Lacassagne Cancer Center in Nice on July 26, 2012. Photo: Reuters/Eric Gaillard

Source Article

Dravet Syndrome Treatment Market | Market to Grow by Over USD 396 Million During 2020-2024

The Dravet syndrome treatment market is set to grow by USD 396.15 million accelerating at a CAGR of over 9%, during the period spanning over 2020-2024. One of the key factors driving growth is the rising strategic alliances. Several pharmaceutical companies are working together to develop drugs for the treatment of Dravet syndrome. Increasing new product launches is a significant trend that will further stimulate market growth. Increasing product launches are making the market more competitive and increasing the availability of drugs for patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201022005201/en/

Technavio has announced its latest market research report titled Global Dravet Syndrome Treatment Market 2020-2024 (Graphic: Business Wire)

To learn more about the global trends impacting the future of market research, download a free sample now

Parent Market Analysis

Technavio categorizes the Dravet syndrome treatment market as a part of the pharmaceutical market within the overall healthcare industry. The parent, pharmaceuticals market covers products and companies engaged in R&D or production of generic drugs, non-generic drugs, and veterinary drugs.

Growth in the healthcare market will be driven by factors such as increasing life expectancy, improving access to better healthcare in emerging economies, rising prevalence of sedentary lifestyle, rising cases of chronic conditions, and rising number of partnerships between pharmaceutical companies.

Technavio’s in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis. Download a Free Sample Report on COVID-19 Impacts

Dravet Syndrome Treatment Market: Segmentation by Geography

The report segments the market by Geography: North America, Europe, Asia, and ROW. 44% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for Dravet syndrome treatment in North America.

Dravet Syndrome Treatment Market: Segmentation by Product

The SGDs segment was leading the market in 2019. This report provides an accurate prediction of the contribution of all the segments to the growth of the Dravet syndrome treatment market size.

Dravet Syndrome Treatment Market: Growth Drivers

The market is driven by the rising number of strategic alliances among vendors. Many vendors in the market are partnering with other vendors to develop effective drugs for the treatment of Dravet syndrome. For instance, in September 2018, Supernus Pharmaceuticals Inc. announced its plans to acquire Biscayne Neurotherapeutics (Biscayne), a privately-held company developing a novel treatment for epilepsy. Similarly, in August 2020, Takeda and Ovid completed the Phase II trials of the Dravet syndrome drug and are planning for the Phase III registrational trials. Such developments are expected to boost market growth during the forecast period.

Dravet Syndrome Treatment Market: Challenges to Overcome

Many patients who do not respond to medications are looking for alternative treatment methods to treat Dravet syndrome. Some of the alternative treatment options such as herbs, vitamins, biofeedback, acupuncture, VNS, and keto diet are gaining popularity, which is affecting the growth of market vendors.

Dravet Syndrome Treatment Market: Vendor landscape

This report provides information on

Roche announces collaboration with Atea Pharmaceuticals to develop a potential oral treatment for COVID-19 patients

  • Roche and Atea partner to jointly develop AT-527, an orally administered direct-acting antiviral (DAA) currently in Phase 2 clinical trials

  • AT-527 has the potential to be the first novel oral antiviral to treat COVID-19 patients outside the hospital setting as well as in the hospital and may also be used in post-exposure prophylactic settings

  • Oral, small-molecule DAAs for COVID-19 patients allow for large-scale manufacturing and facilitate broad patient access

  • If approved, Atea will distribute AT-527 in the United States and Roche will be responsible for global manufacturing and distribution outside the United States

Basel, 22 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and Atea Pharmaceuticals, Inc. announced today that they are joining forces in the fight against COVID-19 to develop, manufacture and distribute AT-527, Atea’s investigational oral direct-acting antiviral, to people around the globe. AT-527 acts by blocking the viral RNA polymerase enzyme needed for viral replication, and is currently being studied in a Phase 2 clinical trial for hospitalised patients with moderate COVID-19. A Phase 3 clinical trial, expected to start in Q1 2021, will explore the potential use in patients outside of the hospital setting. In addition, AT-527 may be developed for post-exposure prophylactic settings.

AT-527, while being a potential oral treatment option for hospitalised patients, also holds the potential to be the first oral treatment option for COVID-19 patients that are not hospitalised.  Additionally, the manufacturing process of small-molecule DAAs allows the ability to produce large quantities of a much needed treatment. If successful, AT-527 could help treat patients early, reduce the progression of the infection, and contribute to decreasing the overall burden on health systems.

The collaboration aims to accelerate the clinical development and manufacturing of AT-527, to investigate its safety and efficacy, and to provide this potential treatment option to patients around the world as quickly as possible. If AT-527 proves safe and effective in clinical trials and regulatory approvals are granted, Atea will be responsible for distributing this treatment option in the U.S, with the option to request Genentech’s support, and Roche will be responsible for distribution outside the United States.

“The ongoing complexities of COVID-19 require multiple lines of defence. By joining forces with Atea, we hope to offer an additional treatment option for hospitalised and non-hospitalised COVID-19 patients, and to ease the burden on hospitals during a global pandemic.” said Bill Anderson, Chief Executive Officer of Roche Pharmaceuticals. “In jointly developing and manufacturing AT-527 at scale, we seek to make this treatment option available to as many people around the world as we possibly can.”

“Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea Pharmaceuticals. “AT-527 is expected to be ideally suited to combat COVID-19 as it inhibits viral replication by interfering with viral RNA polymerase, a key component in the

Convalescent plasma questioned as coronavirus treatment in India: report

Government officials in India are contemplating dropping plasma from coronavirus therapies after a study found it ineffective, per multiple reports.

Dr. Balram Bhargava, chief of the Indian Council of Medical Research (ICMR), said the forthcoming study in the British Medical Journal revealed plasma didn’t lower deaths or prevent progression to severe disease among 464 patients, per Times of India.

Plasma from recovered COVID-19 cases is transfused to critically ill COVID-19 patients, with the hope that the antibodies will help the patient fight or neutralize the disease. 

“We have discussed this in the national task force and are discussing further now with the joint monitoring group that this [plasma therapy] may be deleted from the national guidelines,” Bhargava said, per the outlet. “That discussion is ongoing and more or less we are reaching towards that.” 

Plasma from recovered COVID-19 cases is transfused to critically ill COVID-19 patients, with the hope that the antibodies will help the patient fight or neutralize the disease. (iStock)

Plasma from recovered COVID-19 cases is transfused to critically ill COVID-19 patients, with the hope that the antibodies will help the patient fight or neutralize the disease. (iStock)

CLICK HERE FOR FULL CORONAVIRUS COVERAGE

However, others still have hope.

Satyendar Jain, Delhi health minister, on Wednesday reportedly discussed 2,000 patients who improved from the therapy, touting plasma for saving his own life, one outlet wrote.

“Even America has acknowledged its benefit,” Jain said, per The Economic Times. “Delhi in a way is a pioneer in it and plasma therapy benefits have been seen. You should go and ask family members of those patients who were administered the plasma therapy,” he said.

President Trump announced FDA emergency approval for plasma in August, though top experts, namely Dr. Anthony Fauci and Dr. Francis Collins, voiced concerns over inadequate evidence shortly before the approval which temporarily paused the process. 

WHO’S AT RISK FOR ‘LONG COVID’? STUDY SUGGESTS MOST VULNERABLE 

“This is a powerful therapy that transfuses very, very strong antibodies from the blood of recovered patients to help treat patients battling a current infection,” Trump had said, adding that the authorization would “expand access to this treatment.”

On its webpage, the FDA notes a “statistically significant 37% reduction in mortality in those treated with high titer convalescent plasma,” or in simpler terms, plasma with higher levels of antibodies.

A study by the Mayo Clinic of over 35,000 patients found that plasma with high antibody levels “significantly reduced mortality” in hospitalized COVID-19 patients, 52% of whom were in intensive care.

When the treatment was administered early (within three days), there were fewer deaths.

Fox News Bradford Betz contributed to this article.

CLICK HERE FOR THE FOX NEWS APP

Source Article

The global constipation treatment market is expected to reach US$ 13,386.19 million in 2027 from US$ 8,533.89 million in 2019

The market is estimated to grow with a CAGR of 5. 9% from 2020-2027. The increasing number of FDA approvals and drug development activities are likely to accelerate the market’s growth during the forecast period.

New York, Oct. 21, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Constipation Treatment Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Therapeutic ; Disease ; Distribution Channel, and Geography” – https://www.reportlinker.com/p05978062/?utm_source=GNW
The majority of the established and new players are coming forward to manufacture drugs for the disease, which will lead to the high availability of the drugs in the market.

This availability of drugs is expected to boost consumption, and hence the constipation treatment market. For instance, in 2019, Ardelyx, Inc. got FDA approval for its Ibsrela (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. The newly approved drug is a minimally-absorbed small molecule that acts locally in the gastrointestinal (GI) tract to decrease the abdominal pain and increase the bowel movements in IBS-C patients. Similarly, in January 2018, Synergy Pharmaceuticals Inc. received FDA’s approval for TRULANCE (plecanatide) 3 mg tablet/ per day to treat irritable bowel syndrome with constipation (IBS-C) in adults. TRULANCE was already approved as a medicine for treating chronic idiopathic constipation (CIC) in adults.

The constipation treatment market is projected to witness the introduction of generic drugs, which will eventually positively impact the growth of the market.For instance, in 2020, Teva Pharmaceutical, and Israel based drug manufacturing company, received FDA approval for its first generic version irritable bowel syndrome drug Linzess (linaclotide).

Additionally, according to company estimates, the drug is anticipated to observe thriving sales in the market. Likewise, in November 2018, EA Pharma Co., Ltd. in Japan has launched its MOVICOL in powdered form. The product is the first polyethylene glycol preparation prescribed to treat chronic constipation in adults and children age two years and above. Thus, due to the number of product launches in the market, the constipation treatment market will flourish during the forecast period.
Based on therapeutic, the constipation treatment market is segmented into laxatives, chloride channel activators, peripherally acting mu-opioid receptor antagonists, GC-C agonists, and 5-HT4 receptor agonists.The laxatives segment held the largest share of the market in 2019.

However, GC-C agonists segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on disease, the constipation treatment market is segmented into chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. The chronic idiopathic constipation segment held the largest share of the market in 2019, and is estimated to register the highest CAGR in the market during the forecast period.
Based on distribution channel, the constipation treatment market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held the largest share of the market in 2019, and is estimated to register the highest CAGR of 6.4% in the market during the forecast period.
The Food and Drug Administration (FDA), Canadian Association

Water Treatment Biocides Market Forecast to 2027

The global water treatment biocides market was valued at US$ 3,723. 67 million in 2019 and is projected to reach US$ 5,754. 43 million by 2027; it is expected to grow at a CAGR of 5. 7% from 2020 to 2027.

New York, Oct. 20, 2020 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Water Treatment Biocides Market Forecast to 2027 – COVID-19 Impact and Global Analysis by Product Type and Application” – https://www.reportlinker.com/p05978107/?utm_source=GNW

Water treatment biocides are chemical agents used in water treatment processes.They are synthesized to eliminate microorganisms of all life stages and sizes.

They are formulated to control the microbial growth in potable water, process water, open cooling systems, and down water services.The water treatment biocides are mainly utilized for municipal water treatment, oil & gas, power plants, pulp & paper, mining, and swimming pools.

The oil and gas industry is fueling the growth of the global water treatment biocides market to a greater extent.The oil and gas segment is expected to lead the market over the forecast period.

Moreover, rising oil & gas exploration activities in countries, including Canada and the US, are fueling the demand for water treatment biocides in the oil & gas industry. Municipal water treatment, mining, and swimming pools are some of the niche applications where the water treatment biocides market has witnessed astonishing growth over the past few years. Increasing use of non-oxidizing biocides in pulp & paper industry and power plants is expected to create lucrative opportunities for the market players.

Based on application, the water treatment biocides market is segmented into municipal water treatment, Oil & Gas, power plants, pulp & paper, mining, swimming pools, and others.The oil & gas segment held the largest share in the global water treatment biocides market in 2019.

Biocides are used in all stages of oilfield development, from the initial drilling of the wells and the day to day production of Oil & Gas, to all aspects of the maintenance of the field.They play an important role in the life of an oilfield.

Also, they are a valuable tool in ensuring that Oil & Gas are produced safely and reliably. There are different kinds of biocides that are used in Oil & Gas industry.

In terms of product type, the global water treatment biocides market is segmented into oxidizing biocides and nonoxidizing biocides.Nonoxidizing biocides chemicals work through various exterminating processes, such as interfering with reproduction, stopping respiration, or lysing the cell walls.

Nonoxidizing biocides can be fed continuously to achieve a high enough concentration for a long enough period of time to kill the bacteria.

The water treatment biocides market is segmented into North America, Europe, Asia Pacific, South America, and the Middle East & Africa.Asia Pacific is estimated to register the fastest CAGR in the market during the forecast period.

An increase in disposable per capita income leads to higher demand for better lifestyle and pure drinking water, which further boosts the market for water treatment biocides in this region.